Comparative Pharmacology
Head-to-head clinical analysis: PEDMARK versus RAVICTI.
Head-to-head clinical analysis: PEDMARK versus RAVICTI.
PEDMARK vs RAVICTI
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Sodium thiosulfate acts as a chemoprotectant by binding to and neutralizing reactive platinum compounds, thereby reducing platinum-induced cytotoxicity in normal tissues, including the cochlea. It does not interfere with the antitumor activity of cisplatin.
RAVICTI (glycerol phenylbutyrate) is a prodrug that is converted to phenylacetate, which conjugates with glutamine via the enzyme phenylacetyl-CoA ligase to form phenylacetylglutamine. Phenylacetylglutamine is then excreted in the urine, thereby removing waste nitrogen and providing an alternative pathway for ammonia excretion in patients with urea cycle disorders.
20-40 mg administered intravenously over 3-5 minutes, every 4 hours as needed for breakthrough pain; for opioid-tolerant patients, initiate at 20 mg, titrate in 10 mg increments to efficacy or 80 mg maximum single dose.
Adults: 2.5 mL/m² orally once daily; increase weekly as needed based on ammonia levels; usual maintenance dose range 2.5-12.5 mL/m² daily; maximum daily dose 17.5 mL/m².
None Documented
None Documented
Terminal elimination half-life: 12-18 hours; clinically relevant for once-daily dosing in stable patients
Terminal elimination half-life of phenylbutyrate (parent) is approximately 0.5-1.0 h; the active metabolite phenylacetate has a half-life of about 1.0-1.5 h; the major metabolite phenylacetylglutamine has a half-life of approximately 4-6 h. Clinically, the half-life of phenylacetate is relevant for monitoring ammonia levels.
Renal: 60-70% as unchanged drug; fecal: 20-30% as metabolites; biliary: <5%
Renal: approximately 11% as phenylacetylglutamine; fecal: <1% as parent drug; metabolism via conjugation in liver to phenylacetylglutamine, which is renally excreted
Category C
Category C
Ammonia Scavenger
Ammonia Scavenger